Press Releases

BioMS Medical Announces its Intention to Increase its Normal Course Issuer Bid

Edmonton, Alberta, May 20, 2005 - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis, announced today that it is increasing the number of Class A common shares which may be purchased under its normal course issuer bid from 200,000 shares to 1,000,000 shares, which represents approximately 1.9% of the 51,859,466 issued and outstanding Class A common shares as of August 12, 2004 and approximately 1.6% of the 63,366,766 issued and outstanding Class A common shares as of the date hereof.

The bid is being conducted pursuant to the rules of the Toronto Stock Exchange ("TSX") and the price at which the Company will purchase its shares will be the market price thereof at the time of acquisition. Any common shares acquired by the Company will be cancelled. Since the commencement of the bid on August 15, 2004, the Company has purchased 167,000 Class A common shares at an average price of $3.01 per share under the bid. The bid expires on August 14, 2005.

"BioMS Medical has a strong cash position and the Board believes that the market price of the common shares may not fully reflect the value of the Company's business and its future business prospects," said Clifford Giese, Chairman of BioMS Medical. "As a result, the Board has concluded that the purchase and cancellation of the common shares may represent an appropriate and desirable use of the Company's funds and provide market stability."

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.